CD8A and neoplasm: Furthermore, PERK inhibition with the small molecule inhibitor GSK2606414 reduced the mitochondrial ROS levels in CD8+ tumor infiltrating T cells and enhanced the efficacy of anti PD-1 immunotherapy response in a mouse sarcoma model [188].